The 2024 World Conference on Lung Cancer is taking place in San Diego from September 7th to 10th! Some key abstracts have already been released. Here’s an overview of the OA12 oral presentation session on “Multimodal Treatment of Stage III Lung Cancer”:
OA12.03 – LAURA Study: Osimertinib After Definitive CRT in Unresectable Stage III EGFR-mutated NSCLC – Safety Outcomes from Phase 3 Study
OA12.04 – SQUAT Trial (WJOG 12119L): Neoadjuvant Concurrent Chemo-Immuno-Radiation Therapy Followed by Surgery for Stage III-N2 NSCLC
OA12.05 – APOLO Trial: Phase II Study of Induction Chemo-Immunotherapy Plus Chemoradiotherapy and Maintenance Immunotherapy in Stage III NSCLC
OA12.06 – PACIFIC-BRAZIL Study (LACOG 2218): Intensified Chemo-Immuno-Radiotherapy with Durvalumab for Stage III NSCLCs
More updates to come from WCLC 2024!
